US 10,501,546 B2 · Insulin immunoglobulin fusion proteins

Abstract

Disclosed herein are immunoglobulin fusion proteins comprising an insulin therapeutic peptide and an immunoglobulin region that targets the insulin therapeutic peptide to the liver of an individual in need thereof. Further disclosed herein are compositions comprising the immunoglobulin fusion proteins and methods for using the immunoglobulin fusion proteins for the treatment or prevention of a disease or condition in a subject, for example, diabetes and diabetes related conditions.

Claims20

Dependent claims

An immunoglobulin for specific binding to asialoglycoprotein receptor (ASGPR), the immunoglobulin comprising:

a) a heavy chain sequence comprising (i) SEQ ID NO:
45, SEQ ID NO:
55, and SEQ ID NO:
47;
or (ii) SEQ ID NO:
45, SEQ ID NO:
46, and SEQ ID NO:
47;
and
b) a light chain sequence comprising SEQ ID NO:
48, SEQ ID NO:
49, and SEQ ID NO:
50.

10 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/756,296Filed 2 Sep 2016 · us provisional application

Priority

4 Sep 2015

Published

US 2019/0023794 A124 Jan 2019

Granted

10 Dec 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification8 codes

C07K 16/2851
Against receptors, cell surface antigens or cell surface determinants: against the lectin superfamily, e.g. CD23, CD72
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
C07K 14/62
Hormones: insulins
C07K 16/2854
Against the lectin superfamily, e.g. CD23, CD72: against selectins, e.g. CD62

Insulin immunoglobulin fusion proteins

Life of this patent

Insulin immunoglobulin fusion proteins

Life of this patent

Abstract

Claims20